- Data Provide Evidence of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy in Melanoma and in Combination With Pembrolizumab in Multiple Tumor Types -
- Monotherapy Melanoma Cohort Expanded Based on Achievement of Protocol-Defined Response Criteria -
- Company to Host Investor Webcast at 8:30 a.m. ET on Friday, Sept. 18, 2020 -
PR Newswire
DUBLIN, Sept. 18, 2020